Paper Details

  1. Home
  2. Paper Details

Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.

Author:

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A study of 833 patients with tuberculosis compared five different 6-month treatment regimens. All regimens containing isoniazid and rifampicin achieved a favorable response during treatment. However, the relapse rate after 18 months was significantly lower (1%) for regimens containing streptomycin and pyrazinamide compared to those without pyrazinamide (8%). Regimens containing pyrazinamide also showed good results in patients with isoniazid or streptomycin-resistant tuberculosis. These findings suggest that pyrazinamide is an important component of effective tuberculosis treatment regimens.
Paper Details　
Original Abstract of the Article :
Five 6-month antituberculosis regimens, allocated at random to patients with acid-fast bacilli in their sputum on microscopy, were studied. Four, given 3 times a week throughout, contained isoniazid and rifampicin together with 1. streptomycin, pyrazinamide and ethambutol, 2. streptomycin and pyrazi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0041-3879(82)80044-5

データ提供：米国国立医学図書館（NLM）

Tackling Tuberculosis: A Quest for Effective Treatment Regimens

The fight against tuberculosis (TB) is a relentless battle, with researchers continuously striving to develop effective treatment regimens. This study, conducted by the Hong Kong Chest Service and the British Medical Research Council, investigated the efficacy of various antituberculosis regimens administered over six months. The authors meticulously analyzed the results up to 24 months, shedding light on the long-term impact of these regimens.

Pyrazinamide: A Key Player in TB Treatment Success

The study's findings reveal the remarkable efficacy of pyrazinamide in conjunction with other antituberculosis drugs. The regimens containing pyrazinamide demonstrated significantly lower relapse rates compared to those without pyrazinamide. This suggests that pyrazinamide plays a critical role in preventing the re-emergence of TB bacteria. The data is quite clear, with the relapse rate being 1% for the three-times-weekly regimens containing streptomycin and pyrazinamide, but a much higher 8% for the regimen without pyrazinamide.

A Glimpse into the Future of TB Treatment

This research provides invaluable insights into the development of effective TB treatment regimens. The findings highlight the pivotal role of pyrazinamide in achieving long-term success. These findings have far-reaching implications, offering hope for those battling this debilitating disease. With continued research and development, we can hope to one day eliminate TB as a global health threat.

Dr.Camel's Conclusion

The study demonstrates the importance of pyrazinamide in TB treatment, highlighting its effectiveness in controlling the disease. Just like a camel can navigate a desert with the help of a reliable compass, pyrazinamide acts as a guiding force in the battle against TB, helping to prevent the disease from returning. This research offers a glimmer of hope in the ongoing fight against this tenacious disease.

Date :
  1. Date Completed 1983-02-25
  2. Date Revised 2019-09-08
Further Info :

Pubmed ID

6758252

DOI: Digital Object Identifier

10.1016/s0041-3879(82)80044-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.